# PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months

> **NCT07333352** · PHASE2 · RECRUITING · sponsor: **Shanghai Reinovax Biologics Co.,LTD** · enrollment: 480 (estimated)

## Conditions studied

- Pneumococcal Infectious Disease

## Interventions

- **BIOLOGICAL:** 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700)
- **BIOLOGICAL:** 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13)

## Key facts

- **NCT ID:** NCT07333352
- **Lead sponsor:** Shanghai Reinovax Biologics Co.,LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-11
- **Primary completion:** 2027-07
- **Final completion:** 2027-08
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07333352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07333352, "PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07333352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*